Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Feedback LSE:FDBK London Ordinary Share GB0003340550 ORD 0.25P
  Price Change % Change Share Price Shares Traded Last Trade
  -0.075p -8.57% 0.80p 1,482,711 09:46:20
Bid Price Offer Price High Price Low Price Open Price
0.75p 0.85p 0.875p 0.80p 0.875p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Electronic & Electrical Equipment 0.47 -0.30 -0.11 3.0

Feedback (FDBK) Latest News

More Feedback News
Feedback Takeover Rumours

Feedback (FDBK) Share Charts

1 Year Feedback Chart

1 Year Feedback Chart

1 Month Feedback Chart

1 Month Feedback Chart

Intraday Feedback Chart

Intraday Feedback Chart

Feedback (FDBK) Discussions and Chat

Feedback (FDBK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
12:25:180.8347,725394.21O
11:23:160.82124,0211,015.73O
10:01:290.8260,440495.00O
09:58:370.8230,525250.00O
09:16:120.83600,0004,980.00O
View all Feedback trades in real-time

Feedback (FDBK) Top Chat Posts

DateSubject
23/4/2019
09:20
Feedback Daily Update: Feedback is listed in the Electronic & Electrical Equipment sector of the London Stock Exchange with ticker FDBK. The last closing price for Feedback was 0.88p.
Feedback has a 4 week average price of 0.80p and a 12 week average price of 0.80p.
The 1 year high share price is 3.58p while the 1 year low share price is currently 0.80p.
There are currently 373,283,250 shares in issue and the average daily traded volume is 396,245 shares. The market capitalisation of Feedback is £2,986,266.
30/3/2019
15:58
petekand: I am not sure whether that would help at all. They practically all bought in the 1.5p placing and some have bought as high as 3.5p only last year and the result? If the new kid bought some now, I would anticipate the price halving again. The people at the top should be thoroughly ashamed of themselves for allowing this situation to occur in the first place and now seems that all control has been lost and the share price is in free fall and in the hands of corrupt market forces. The answer from the bod is "oh let's hold a proactive meeting in two months time where we can wow more new investors into this pile of nonsense." Yes, I am sure this will go down a treat when they look at the price graph falling off a cliff. AR as the man under who's watch this has taken place needs to be hung and quartered.
25/3/2019
21:31
petekand: Yes I am sure all of us mug investors will be thrilled to hear how world beating our technology is and how they are leading the world with innovative radiology that sees what no others can see. The share price tells us a completely different story however and that is the only indicator which matters and so far pointing to a total failure for the tech and the bod. Zero demand for the shares and sellers falling over each trying to get the hell out of this dogs dinner of a company at any price! How does a price almost halve so soon after an 'oversubscribed' placing at 1.5p? I rather stay at home and read Jack and the Beanstalk than listen to this bods fairytales.
22/3/2019
20:50
lr2: Remember this old Nvidia / TexRAD / Future Processing connection, Duc? Https://blogs.nvidia.com/blog/2017/11/16/detect-cancer-from-ct-scans/ Well, Nvidia announced Project Clara earlier this year and I've been keeping an eye on it. Https://medcitynews.com/2018/09/nvidia-pushes-forward-on-its-project-clara-medical-imaging-project And the Clara healthcare platform provides a "software development kit allowing third-party developers to build applications for medical imaging." Now Nvidia have updated the Clara platform "to make it easier for clinicians to train and adapt deep learning algorithms, while also making the implementation process smoother." Https://medcitynews.com/2019/03/how-nvidia-is-trying-to-overcome-the-barriers-for-ai-in-healthcare/ What's holding back this system? "Data availability – more specifically, the lack of wide ranging annotated data sets – still function as a major limiting factor for training and fine-tuning deep learning algorithms." And isn't that precisely the role of software like Cadran? Also now "Nvidia has released a feature called Clara Deploy which enables organizations to drop in algorithms that connect with existing imaging software." I like the look of what I'm reading tonight. Mind you it won't make an ounce of difference to the share price unless there's an announcement. Then again, Alastair Riddell did say the following not so long ago. "The group is also in ongoing discussions with various medical imaging software companies and service providers to partner with and integrate its TexRAD Lung product within their platforms and potentially sell the software globally."
19/3/2019
22:11
petekand: Never mind meeting the good doctor, I am more worried of waking up tomorrow morning to see a share price less than 1 penny! What a carry on. So what are the logical reasons of this carnage? The ii paid 1.5p so maybe they decided to bail after the drop? Or is it just old fashioned selling to offset tax with fdbk a good candidate? Brexit?
19/3/2019
13:19
davydoo: Thanks Ged, perhaps, but they don't hold much. Maybe it just shows how often and how much founders get diluted to see their idea get to market. Or perhaps the bigger prize is seeing the medical improvements, and the professional recognition, rather than the share price.
19/3/2019
12:49
petekand: I wonder if they could use Texrad to analyse the share price performance to see what comes up that cannot be seen by our naked eyes.
05/2/2019
19:37
tim000: Micro mkt cap shares are usually highly volatile due to the dominance of short-term (ie day) trading, since even fairly small trades can represent a relatively high proportion of the company's mkt cap (and hence will inevitably affect the share price). That in turn tends to drive others to trade in the same direction, resulting in upward/downward momentum. Witness the massive spikes and subsequent retraces for FDBK's share price. I'm sure you all know this. So a company that produces very little operational news is inevitably only going to appeal to longer term investors. Impatient investors are continually selling their stock, because of the opportunity costs of holding FDBK, ie not being able to trade micro cap stocks that are rising sharply. That doesn't mean there is a good reason to sell one's investment in FDBK. Personally I have no intention of selling, I have other funds that I can use to day trade - eg BMV and MATD at the moment!
13/12/2018
10:10
tim000: I think I know why the share price is weak! Reading the Holdings RNSs is a clue. I hold OPG. Look what happened there. The company suddenly had a good set of interims and the share price has gone up about 70%. It will probably continue to rise. I hope for a similar story here. But share price appreciation may only begin upon newsflow. And then I expect the appreciation to be sustained. I know seeing your shares go down is frustrating, but this really is a share where we have to be patient. Incidentally, the IQAI RNS today was interesting. Hopefully FDBK will learn lessons from their experience in getting FDA approval. IQAI are hoping for FDA approval within a year. If FDBK can achieve that, it will be a good result.
22/11/2018
15:27
tim000: To be fair this news is pretty marginal. To get the share price moving up to what we believe would be a more appropriate level, we need a succession of positive trading updates, ideally based on new sales but also any news on product developments, marketing collaborations and progress on getting FDA approval. Versarian's Neill Ricketts is a role model in that respect, and VRS's share price has risen correspondingly. (Of course VRS's graphene has a much larger prospective market than that of FDBK, although both have achieved worldwide interest.)
13/6/2018
11:49
lr2: Yes, but by indicating another money raising they've made it a lot harder for the share price in the short term. I don't blame the board as much as I do Trevor Brown. He decimated the share price by his pernicious selling over the previous 12 months. The board opted to raise a minimal amount at the very low price caused by Trevor Brown but they could have raised some more money (they still had the authority to do so) without calling for a special meeting. That is where, perhaps, they went wrong. Once the market was forewarned of a another likely raising lots of people sold up and pushed the share price downwards. And that is why the share price is where it is. When the clinical version of TexRAD sees light of day, that's when the share price lifts off.
Feedback share price data is direct from the London Stock Exchange
Your Recent History
LSE
FDBK
Feedback
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190423 14:55:23